NICE evidence-based recommendations on lisocabtagene maraleucel (Breyanzi) for for treating relapsed or refractory large B-cell lymphoma in 2 line

Evidence-based recommendations on lisocabtagene maraleucel (Breyanzi) for treating relapsed or refractory large B-cell lymphoma in adults after first-line chemoimmunotherapy when a stem cell transplant is suitable.

Last reviewed: 26 March 2025

Next review: This guidance will be reviewed if there is new evidence that is likely to change the recommendations.

Commercial arrangement

There is a simple discount patient access scheme for lisocabtagene maraleucel. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact UKCommercialEnquiries@bms.com for details.

Recommendations